LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Harvard Bioscience Inc

Gesloten

SectorGezondheidszorg

4.69 -2.29

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.67

Max

4.86

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6M

-2.8M

Verkoop

3.1M

24M

Winstmarge

-11.995

Werknemers

330

EBITDA

51M

52M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.2% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

221M

Vorige openingsprijs

6.98

Vorige sluitingsprijs

4.69

Nieuwssentiment

By Acuity

17%

83%

24 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mrt 2026, 22:51 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mrt 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mrt 2026, 20:31 UTC

Winsten

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mrt 2026, 23:49 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mrt 2026, 23:31 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery -- Market Talk

18 mrt 2026, 22:49 UTC

Marktinformatie

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mrt 2026, 22:41 UTC

Marktinformatie

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mrt 2026, 22:36 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mrt 2026, 22:24 UTC

Winsten

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mrt 2026, 21:58 UTC

Winsten

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mrt 2026, 21:40 UTC

Marktinformatie

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mrt 2026, 21:16 UTC

Marktinformatie

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mrt 2026, 21:00 UTC

Belangrijke Nieuwsgebeurtenissen

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mrt 2026, 20:58 UTC

Winsten

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mrt 2026, 20:41 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:29 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:25 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:17 UTC

Winsten

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mrt 2026, 20:14 UTC

Marktinformatie

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mrt 2026, 20:09 UTC

Winsten

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mrt 2026, 20:07 UTC

Winsten

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mrt 2026, 20:06 UTC

Winsten

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mrt 2026, 20:03 UTC

Winsten

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

23.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6 USD  23.2%

Hoogste 6 USD

Laagste 6 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

24 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat